Insider · CIK 0001359151
Matti Masanovich
Files at CTLT (Catalent, Inc.). First filing -, latest -.
Matti Masanovich files SEC Form 4 as CFO at CTLT (Catalent, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Matti Masanovich has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | CTLT Catalent, Inc. | DDisposition to issuer Common Stock | -76,475 | - | - | 0 | Dec 18, 2024 |
| Dec 18, 2024 | CTLT Catalent, Inc. | AGrant or award Common Stock | +71,691 | $0.00 | $0 | 71,691 | Dec 18, 2024 |
| Dec 18, 2024 | CTLT Catalent, Inc. | DDisposition to issuer Common Stock | -71,691 | - | - | 0 | Dec 18, 2024 |
| Dec 18, 2024 | CTLT Catalent, Inc. | DDisposition to issuer Options to purchase Common Stockderivative | -81,082 | - | - | 0 | Dec 18, 2024 |
Questions about Matti Masanovich
Answered from the filings on this page, as of the latest one.
Is Matti Masanovich buying or selling?
Matti Masanovich has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Matti Masanovich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matti Masanovich has 0.
Where does Matti Masanovich file Form 4?
Matti Masanovich has filed Form 4 at CTLT (Catalent, Inc.) as SVP, Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.